GSK 0001654954-25-001726 6-K Filing: Feb 21, 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares

This notification sets out the vesting details for Person Discharging Managerial Responsibilities ('PDMRs') of Conditional Share Awards over Ordinary Shares made in 2022 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 17 February 2025.

Transaction notification

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	The vesting of Ordinary Shares awarded in 2022 under the Company's<br>Share Value Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£14.1829	24,638

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br>Price
e)	Date<br>of the transaction	2025-02-17
f)	Place<br>of the transaction	N/A
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2022 under the Company's Share Value<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£14.1829	11,580

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br>Price
e)	Date<br>of the transaction	2025-02-17
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	The vesting of Ordinary Shares awarded in 2022 under the Company's<br>Share Value Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£14.1829	10,050

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br>Price
e)	Date<br>of the transaction	2025-02-17
f)	Place<br>of the transaction	N/A
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2022 under the Company's Share Value<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£14.1829	4,724

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br>Price
e)	Date<br>of the transaction	2025-02-17
f)	Place<br>of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: February<br>20, 2025

	By:/s/ VICTORIA<br>WHYTE<br><br>--------------------------

	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GSK plc

GSK 6-K